The effect of cantharidins on leukemic stem cells

International Journal of Cancer

Volumn 124, Issue 9, 2009, Pages 2186-2199

  Dorn, David C ^a   Kou, Cynthia A ^a   Png, Kim J ^a   Moore, Malcolm A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

AML xenograft model; Cantharidin norcantharidin; Leukemic stem cells; LSC in vitro model

Indexed keywords

CANTHARIDIN; CASPASE 8; CASPASE 9; CYTARABINE; DAUNORUBICIN; MYC PROTEIN; NORCANTHARIDIN; PROTEIN NFIL3; PROTEIN P53; TRANSCRIPTION FACTOR SLUG; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; ARYLAMINE ACETYLTRANSFERASE; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CASPASE; ENZYME INHIBITOR; FUSED HETEROCYCLIC RINGS; HLF PROTEIN, HUMAN; MYC PROTEIN, HUMAN; NFIL3 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; STAT5 PROTEIN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CELL LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HEMATOPOIETIC STEM CELL; HLF GENE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GENE; ANIMAL; CANCER STEM CELL; CELL CYCLE; CLONOGENIC ASSAY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FETUS BLOOD; LUMINESCENCE; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; STROMA CELL; SURVIVAL RATE; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; ARYLAMINE N-ACETYLTRANSFERASE; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BICYCLO COMPOUNDS, HETEROCYCLIC; CANTHARIDIN; CASPASES; CELL CYCLE; COLONY-FORMING UNITS ASSAY; CYTARABINE; DAUNORUBICIN; ENZYME INHIBITORS; FEMALE; FETAL BLOOD; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUMINESCENCE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MYC; STAT5 TRANSCRIPTION FACTOR; STROMAL CELLS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63449135103     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24157     Document Type: Article

References (75)

1. Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp Hematol 2007;35:105-116 (Pubitemid 46427988)
2. Chung KY, Morrone G, Schuringa JJ, Wong B, Dorn DC, Moore MA. Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood 2005;105:77-84. (Pubitemid 40053067)
3. Hitzler JK, Soares HD, Drolet DW, Inaba T, O'Connel S, Rosenfeld MG, Morgan JI, Look AT. Expression patterns of the hepatic leukemia factor gene in the nervous system of developing and adult mice. Brain Res 1999;820:1-11. (Pubitemid 29225473)
4. Shojaei F, Trowbridge J, Gallacher L, Yuefei L, Goodale D, Karanu F, Levac K, Bhatia M. Hierarchical and ontogenic positions serve to define the molecular basis of human hematopoietic stem cell behavior. Dev Cell 2005;8:651-663 (Pubitemid 40585289)
5. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002;298:601-604
6. Georgantas RW, III, Tanadve V, Malehorn M, Heimfeld S, Chen C, Carr L, Martinez-Murillo F, Riggins G, Kowalski J, Civin CI. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res 2004;64:4434-4441 (Pubitemid 38856914)
7. Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD, Look AT. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science 1992;257:531-534
8. Crable SC, Anderson KP. A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene. Blood 2003;101:4757-4764 (Pubitemid 36857732)
9. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994;78:45-57. (Pubitemid 24228299)
10. Inukai T, Inoue A, Kurosawa H, Goi K, Shinjyo T, Ozawa K, Mao M, Inaba T, Look AT. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 1999;4:343-352 (Pubitemid 29499787)
11. Bermejo-Rodriguez C, Perez-Caro M, Perez-Mancera PA, Sanchez-Beato M, Piris MA, Sanchez-Garcia I. Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts. Genomics 2006;87:113-118 (Pubitemid 43005107)
12. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997;278:1059-1064 (Pubitemid 27517875)
13. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996;87:1211-1224 (Pubitemid 26056883)
14. Begbie M, Mueller C, Lillicrap D. Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes. DNA Cell Biol 1999;18:165-173 (Pubitemid 29095996)
15. Zhang JP, Ying K, Xiao ZY, Zhou B, Huang QS, Wu HM, Yin M, Xie Y, Mao YM, Rui YC. Analysis of gene expression profiles in human HL-60 cell exposed to cantharidin using cDNA microarray. Int J Cancer 2004;108:212-218 (Pubitemid 37541773)
16. Yeung J, O'Sullivan E, Hubank M, Brady HJ. E4BP4 expression is regulated by the t(17;19)-associated oncoprotein E2A-HLF in pro-B cells. Br J Haematol 2004;125:560-567 (Pubitemid 38747957)
17. Ikushima S, Inukai T, Inaba T, Nimer SD, Cleveland JL, Look AT. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. Proc Natl Acad Sci USA 1997;94:2609-2614 (Pubitemid 27136923)
18. Ellenhorn MJ. Ellenhorn's medical toxicology: diagnosis and treatment of human poisoning, 2nd edn. Baltimore, MD: Williams & Wilkins, 1997.
19. Till JS, Majmudar BN. Cantharidin poisoning. South Med J 1981;74:444-447 (Pubitemid 12203629)
20. Southcott RV. Injuries from coleoptera. Med J Aust 1989;151:654-659 (Pubitemid 20021271)
21. Carrel JE, McCairel MH, Slagle AJ, Doom JP, Brill J, McCormick JP. Cantharidin production in a blister beetle. Experientia 1993;49:171-174 (Pubitemid 23063420)
22. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989;26:147-162 (Pubitemid 19257209)
23. Cheng KC, Lee HM, Shum SF, Yip CP. A fatality due to the use of cantharides from Mylabris phalerata as an abortifacient. Med Sci Law 1990;30:336-340 (Pubitemid 20309256)
24. Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol 2001;137:1357-1360 (Pubitemid 32954188)
25. Bertaux B, Prost C, Heslan M, Dubertret L. Cantharide acantholysis: endogenous protease activation leading to desmosomal plaque dissolution. Br J Dermatol 1988;118:157-165 (Pubitemid 18162414)
26. McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, Baldwin ML. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 2000;10:1687-1690 (Pubitemid 30495241)
27. Einbinder JM, Parshley MS, Walzer RA, Sanders SL. The effect of cantharidin on epithelial cells in tissue culture. J Invest Dermatol 1969;52:291-303.
28. Wu JZ, Situ ZQ, Chen JY, Liu B, Wang W. Chemosensitivity of salivary gland and oral cancer cell lines. Chin Med J (Engl) 1992;105:1026-1028 (Pubitemid 23034278)
29. Sakoff JA, Ackland SP, Baldwin ML, Keane MA, McCluskey A. Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues. Invest New Drugs 2002;20:1-11. (Pubitemid 34251646)
30. Li YM, Casida JE. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci USA 1992;89:11867-11870 (Pubitemid 23004745)
31. McCluskey A, Ackland SP, Bowyer MC, Baldwin ML, Garner J, Walkom CC, Sakoff JA. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines. Bioorg Chem 2003;31:68-79. (Pubitemid 36411927)
32. Cohen P. The structure and regulation of protein phosphatases. Annu Rev Biochem 1989;58:453-508. (Pubitemid 19172978)
33. Ingebritsen TS, Stewart AA, Cohen P. The protein phosphatases involved in cellular regulation. 6. Measurement of type-1 and type-2 protein phosphatases in extracts of mammalian tissues; an assessment of their physiological roles. Eur J Biochem 1983;132:297-307.
34. Shenolikar S, Nairn AC. Protein phosphatases: recent progress. Adv Second Messenger Phosphoprotein Res 1991;23:1-121.
35. Cohen PT, Brewis ND, Hughes V, Mann DJ. Protein serine/threonine phosphatases; an expanding family. FEBS Lett 1990;268:355-359 (Pubitemid 20241342)
36. Chen YJ, Kuo CD, Tsai YM, Yu CC, Wang GS, Liao HF. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs 2008;19:55-64. (Pubitemid 350190968)
37. Liao HF, Su SL, Chen YJ, Chou CH, Kuo CD. Norcantharidin preferentially induces apoptosis in human leukemic Jurkat cells without affecting viability of normal blood mononuclear cells. Food Chem Toxicol 2007;45:1678-1687
38. Liu XH, Blazsek I, Comisso M, Legras S, Marion S, Quittet P, Anjo A, Wang GS, Misset JL. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 1995;31A:953-963
39. Zheng LH, Bao YL, Wu Y, Yu CL, Meng X, Li YX. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett 2008;272:102-109.
40. Jiang TL, Salmon SE, Liu RM. Activity of camptothecin, harringtonin, cantharidin and curcumae in the human tumor stem cell assay. Eur J Cancer Clin Oncol 1983;19:263-270 (Pubitemid 13155865)
41. Wu KD, Cho YS, Katz J, Ponomarev V, Chen-Kiang S, Danishefsky SJ, Moore MA. Investigation of antitumor effects of synthetic epothilone analogs in human myeloma models in vitro and in vivo. Proc Natl Acad Sci USA 2005;102:10640-10645 (Pubitemid 41061607)
42. Efferth T, Davey M, Olbrich A, Rucker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis 2002;28:160-168 (Pubitemid 34743750)
43. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12:1333-1337 (Pubitemid 28442377)
44. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, Kato K, Kojima S, Matsuyama T. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999;33:525-529
45. Piacibello W, Sanavio F, Severino A, Dane A, Gammaitoni L, Fagioli F, Perissinotto E, Cavalloni G, Kollet O, Lapidot T, Aglietta M. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(1) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999;93:3736-3749
46. Kusadasi N, van Soest PL, Mayen AE, Koevoet JL, Ploemacher RE. Successful short-term ex vivo expansion of NOD/SCID repopulating ability and CAFC week 6 from umbilical cord blood. Leukemia 2000;14:1944-1953.
47. Kanai M, Hirayama F, Yamaguchi M, Ohkawara J, Sato N, Fukazawa K, Yamashita K, Kuwabara M, Ikeda H, Ikebuchi K. Stromal cell-dependent ex vivo expansion of human cord blood progenitors and augmentation of transplantable stem cell activity. Bone Marrow Transplant 2000;26:837-844 (Pubitemid 30195467)
48. Schuringa JJ, Chung KY, Morrone G, Moore MA. Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. J Exp Med 2004;200:623-635 (Pubitemid 39258311)
49. van der Kolk DM, de Vries EG, Muller M, Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002;43:685-701. (Pubitemid 34428655)
50. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W, Kratz-Albers K, Serve S, Steur C, Buchner T, Kienast J, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-3914
51. Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164-3173
52. Wierenga AT, Schepers H, Moore MA, Vellenga E, Schuringa JJ. STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/ EBPalpha. Blood 2006;107:4326-4333 (Pubitemid 43801357)
53. Cowell IG, Hurst HC. Transcriptional repression by the human bZIP factor E4BP4: definition of a minimal repression domain. Nucleic Acids Res 1994;22:59-65. (Pubitemid 24984472)
54. Cowell IG, Skinner A, Hurst HC. Transcriptional repression by a novel member of the bZIP family of transcription factors. Mol Cell Biol 1992;12:3070-3077
55. Zhang W, Zhang J, Kornuc M, Kwan K, Frank R, Nimer SD. Molecular cloning and characterization of NF-IL3A, a transcriptional activator of the human interleukin-3 promoter. Mol Cell Biol 1995;15:6055-6063
56. Kuribara R, Kinoshita T, Miyajima A, Shinjyo T, Yoshihara T, Inukai T, Ozawa K, Look AT, Inaba T. Two distinct interleukin-3-mediated signal pathways, Ras-NFIL3 (E4BP4) and Bcl-xL, regulate the survival of murine pro-B lymphocytes. Mol Cell Biol 1999;19:2754-2762 (Pubitemid 29144519)
57. Chen YJ, Shieh CJ, Tsai TH, Kuo CD, Ho LT, Liu TY, Liao HF. Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs 2005;16:293-299 (Pubitemid 40283944)
58. To KK, Ho YP, Au-Yeung SC. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin. Cancer Lett 2005;223:227-237 (Pubitemid 40719621)
59. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:528-541 (Pubitemid 350199070)
60. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512
61. Avery JS. A case of acute cantharides poisoning. Lancet 1908;2:800-801
62. Tagwireyi D, Ball DE, Loga PJ, Moyo S. Cantharidin poisoning due to "Blister beetle" ingestion. Toxicon 2000;38:1865-1869.
63. Matsuzawa M, Graziano M, Casida J. Endothal and cantharidin analogues: relation of structure to herbicidal activity and mammalian toxicity. J Agric Food Chem 1987;35:823-829
64. Karras DJ, Farrell SE, Harrigan RA, Henretig FM, Gealt L. Poisoning from "Spanish fly" (cantharidin). Am J Emerg Med 1996;14:478-483 (Pubitemid 26272253)
65. Mallari RQ, Saif M, Elbualy MS, Sapru A. Ingestion of a blister beetle (Mecoidae family). Pediatrics 1996;98:458-459 (Pubitemid 26295853)
66. Cowell IG. E4BP4/NFIL3, a PAR-related bZIP factor with many roles. Bioessays 2002;24:1023-1029 (Pubitemid 35326160)
67. Yan MS, Xiue S, Wei LX, Piao XH. The preliminary observation on immunosuppressive effect of norcantharidin in mice. Immunopharmacol Immunotoxicol 1993;15:79-85. (Pubitemid 23069481)
68. Linck B, Boknik P, Knapp J, Muller FU, Neumann J, Schmitz W, Vahlensieck U. Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br J Pharmacol 1996;119:545-550 (Pubitemid 26335318)
69. Knapp J, Boknik P, Linck B, Luss H, Muller FU, Petertonjes L, Schmitz W, Neumann J. Cantharidin enhances norepinephrine-induced vasoconstriction in an endothelium-dependent fashion. J Pharmacol Exp Ther 2000;294:620-626 (Pubitemid 30490837)
70. Pandey AV, Mellon SH, Miller WL. Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J Biol Chem 2003;278:2837-2844 (Pubitemid 36801187)
71. Hill TA, Stewart SG, Ackland SP, Gilbert J, Sauer B, Sakoff JA, McCluskey A. Norcantharimides, synthesis and anticancer activity: synthesis of new norcantharidin analogues and their anticancer evaluation. Bioorg Med Chem 2007;15:6126-6134 (Pubitemid 47088962)
72. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Wong RS, Cheng GY, Tang WK, Teo IT, Cheung F, Cheng CH, Chan AS, et al. Apoptogenic activity of a synthetic cantharimide in leukaemia: implication on its structural activity relationship. Int J Mol Med 2006;18:1217-1221
73. Kok SH, Chui CH, Lam WS, Chen J, Lau FY, Wong RS, Cheng GY, Tang WK, Cheng CH, Tang JC, Chan AS. Mechanistic insight into a novel synthetic cantharidin analogue in a leukaemia model. Int J Mol Med 2006;18:375-379
74. Chang CC, Liu DZ, Lin SY, Liang HJ, Hou WC, Huang WJ, Chang CH, Ho FM, Liang YC. Liposome encapsulation reduces cantharidin toxicity. Food Chem Toxicol 2008;46:3116-3121
75. Price WA, Stobbe CC, Park SJ, Chapman JD. Radiosensitization of tumour cells by cantharidin and some analogues. Int J Radiat Biol 2004;80:269-279 (Pubitemid 38736756)